Abstract
Activation of Janus kinase 2 (JAK2) by chromosomal translocations or point mutations is a frequent event in haematological malignancies1,2,3,4,5,6. JAK2 is a non-receptor tyrosine kinase that regulates several cellular processes by inducing cytoplasmic signalling cascades. Here we show that human JAK2 is present in the nucleus of haematopoietic cells and directly phosphorylates Tyr 41 (Y41) on histone H3. Heterochromatin protein 1α (HP1α), but not HP1β, specifically binds to this region of H3 through its chromo-shadow domain. Phosphorylation of H3Y41 by JAK2 prevents this binding. Inhibition of JAK2 activity in human leukaemic cells decreases both the expression of the haematopoietic oncogene lmo2 and the phosphorylation of H3Y41 at its promoter, while simultaneously increasing the binding of HP1α at the same site. These results identify a previously unrecognized nuclear role for JAK2 in the phosphorylation of H3Y41 and reveal a direct mechanistic link between two genes, jak2 and lmo2, involved in normal haematopoiesis and leukaemia1,2,3,4,5,6,7,8,9.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Campbell, P. J. & Green, A. R. The myeloproliferative disorders. N. Engl. J. Med. 355, 2452–2466 (2006)
Levine, R. L., Pardanani, A., Tefferi, A. & Gilliland, D. G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Rev. Cancer 7, 673–683 (2007)
Scott, L. M. et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356, 459–468 (2007)
Lacronique, V. et al. A TEL–JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309–1312 (1997)
Bercovich, D. et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down’s syndrome. Lancet 372, 1484–1492 (2008)
Mullighan, C. G. et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 106, 9414–9418 (2009)
McCormack, M. P. & Rabbitts, T. H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 350, 913–922 (2004)
Neubauer, H. et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397–409 (1998)
Yamada, Y. et al. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc. Natl Acad. Sci. USA 95, 3890–3895 (1998)
Walz, C. et al. Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J. Biol. Chem. 281, 18177–18183 (2006)
Zhao, R. et al. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N. Engl. J. Med. 359, 2778–2789 (2008)
Plo, I. et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 112, 1402–1412 (2008)
Shi, S. et al. JAK signaling globally counteracts heterochromatic gene silencing. Nature Genet. 38, 1071–1076 (2006)
Quentmeier, H., MacLeod, R. A., Zaborski, M. & Drexler, H. G. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 20, 471–476 (2006)
Watling, D. et al. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-γ signal transduction pathway. Nature 366, 166–170 (1993)
Pardanani, A. et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21, 1658–1668 (2007)
Xie, S. et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20, 6188–6195 (2001)
Squires, M. S. et al. AT9283, a potent inhibitor of JAK2, is active in JAK2 V617F myeloproliferative disease models. Blood 110 Abstract 3537 (2007)
Bannister, A. J. et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410, 120–124 (2001)
Lachner, M., O’Carroll, D., Rea, S., Mechtler, K. & Jenuwein, T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410, 116–120 (2001)
Wood, A. D. et al. Id1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F–STAT5 signalling. Blood 114, 1820–1830 (2009)
Donaldson, I. J., Chapman, M. & Gottgens, B. TFBScluster: a resource for the characterization of transcriptional regulatory networks. Bioinformatics 21, 3058–3059 (2005)
Ma, A. C., Ward, A. C., Liang, R. & Leung, A. Y. The role of jak2a in zebrafish hematopoiesis. Blood 110, 1824–1830 (2007)
Ferreira, H., Somers, J., Webster, R., Flaus, A. & Owen-Hughes, T. Histone tails and the H3 αN helix regulate nucleosome mobility and stability. Mol. Cell. Biol. 27, 4037–4048 (2007)
Cummings, W. J. et al. Chromatin structure regulates gene conversion. PLoS Biol. 5, e246 (2007)
Panteleeva, I. et al. HP1α guides neuronal fate by timing E2F-targeted genes silencing during terminal differentiation. EMBO J. 26, 3616–3628 (2007)
Yamagishi, Y., Sakuno, T., Shimura, M. & Watanabe, Y. Heterochromatin links to centromeric protection by recruiting shugoshin. Nature 455, 251–255 (2008)
Osborn, L., Kunkel, S. & Nabel, G. J. Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc. Natl Acad. Sci. USA 86, 2336–2340 (1989)
Dyer, P. N. et al. Reconstitution of nucleosome core particles from recombinant histones and DNA. Methods Enzymol. 375, 23–44 (2004)
Bannister, A. J. & Kouzarides, T. The CBP co-activator is a histone acetyltransferase. Nature 384, 641–643 (1996)
Krude, T. Mimosine arrests proliferating human cells before onset of DNA replication in a dose-dependent manner. Exp. Cell Res. 247, 148–159 (1999)
Krude, T. Initiation of human DNA replication in vitro using nuclei from cells arrested at an initiation-competent state. J. Biol. Chem. 275, 13699–13707 (2000)
Nielsen, S. J. et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 412, 561–565 (2001)
Acknowledgements
We thank P. Flicek, S. Wilder, B. Huntly, S. J. Dawson and all the members of the A.R.G., B.G. and T.K. laboratories, in particular P. Hurd, B. Xhemalce, E. J. Baxter and P. Beer, for helpful discussions; A. Wood for sharing unpublished data; and J. LeQuesne for help with image analysis. This work was supported by PhD fellowship grants to M.A.D. from the General Sir John Monash Foundation, the Cambridge Commonwealth Trust and Raymond and Beverly Sackler. The Green (A.R.G.) laboratory is funded by the UK Leukaemia Research Fund, the Wellcome Trust, the Leukemia & Lymphoma Society of America and the National Institute for Health Research Cambridge Biomedical Research Centre. The Göttgens (B.G.) laboratory is funded by the Leukaemia Research Fund, Cancer Research UK, the Leukemia & Lymphoma Society of America and a Medical Research Council studentship to S.D.F. The Kouzarides (T.K.) laboratory is funded by grants from Cancer Research UK and the 6th Research Framework Programme of the European Union (Epitron, HEROIC and SMARTER).
Author Contributions M.A.D. and A.J.B. designed experiments, performed research, interpreted data and wrote the manuscript. S.D.F. and T.B. performed experiments. B.G., A.R.G. and T.K. designed experiments, interpreted data and wrote the manuscript. M.A.D. and A.J.B. are joint first authors. A.R.G. and T.K. are joint senior authors.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
[COMPETING INTERESTS: T.K. is a director of Abcam Ltd, and A.R.G. is on the clinical advisory board for Astex Therapeutics, Cambridge, UK. The remaining authors declare no competing interests.]
Supplementary information
Supplementary Information
This file contains Supplementary Figures 1-12 with Legends and Supplementary Table 1. (PDF 2681 kb)
Rights and permissions
About this article
Cite this article
Dawson, M., Bannister, A., Göttgens, B. et al. JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin. Nature 461, 819–822 (2009). https://doi.org/10.1038/nature08448
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature08448
This article is cited by
-
Tyrosine phosphorylation of CARM1 promotes its enzymatic activity and alters its target specificity
Nature Communications (2024)
-
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Signal Transduction and Targeted Therapy (2023)
-
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Signal Transduction and Targeted Therapy (2023)
-
A novel germline hyperactivating JAK2 mutation L604F
Annals of Hematology (2023)
-
EBF1–JAK2 inhibits the PAX5 function through physical interaction with PAX5 and kinase activity
International Journal of Hematology (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.